HER2

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998 • 667 citations

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

1998 • 628 citations

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

1992 • 466 citations

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1995 • 312 citations

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

1998 • 270 citations

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1994 • 250 citations

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1999 • 221 citations

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

1998 • 171 citations

No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1998 • 167 citations

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

1995 • 166 citations

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

1997 • 160 citations

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

1997 • 91 citations

P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy

1998 • 79 citations

A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923

2000 • 53 citations

Herceptin (R) improves time to progression following chemotherapy in women with metastatic breast cancer

1999 • 4 citations